Abstract: The present invention provides a highly controlled complex comprising an antibody and ferritin particles. More specifically, the present invention provides the inventions of a complex or salt thereof comprising (A) one IgG antibody and (B) two human ferritin particles comprising one or more human ferritin H chains linked thereto; and methods for producing the same.

Abstract: Controlling the number of modifying groups introduced into a surface of ferritin affords a modified ferritin containing a human ferritin H chain, in which the human ferritin H chain contains a modifying group that is covalently bonded specifically to a cysteine residue at position 91 and/or position 103 according to a reference position of a natural human ferritin H chain.

Abstract: A method for producing a protein is provided. An objective protein is produced by culturing in a culture medium Talaromyces cellulolyticus having an objective protein-producing ability, which has been modified so that the activity of a Pep4 protein is reduced.

Abstract: Enantiomers may be analyzed by: (1) reacting a mixture of a first compound and a second compound that are a pair of enantiomers with an axially chiral compound that is one of a pair of axially chiral isomers, to generate a derivative mixture containing a first derivative obtained by a reaction of the first compound with the axially chiral compound and a second derivative obtained by a reaction of the second compound with the axially chiral compound; (2) separating the first derivative and the second derivative in the derivative mixture; and (3) detecting the separated first derivative and second derivative by mass spectrometry.

Abstract: Peptides consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO: 1), LIVTQTMKG (SEQ ID NO: 2), LIVTQTMK (SEQ ID NO: 3), IVTQTMKGL (SEQ ID NO: 4), IVTQTMKG (SEQ ID NO: 5), and VTQTMKGL (SEQ ID NO: 6) are useful for improving intestinal barrier function, for suppressing blood glucose elevation, for improving insulin sensitivity, for promoting FGF21 secretion, for suppressing stress or protecting nerves, or for reducing fatigue.

Abstract: Compounds having an affinity substance to an antibody, a cleavable portion, and a reactive group, or a salt thereof, are represented by the following Formula (I): A-L-B—R??(I) wherein A is an affinity substance to an antibody, L is a cleavable linker that is a divalent group comprising a cleavable portion, B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group, and R is a reactive group to the antibody, wherein the affinity substance to an antibody is a polypeptide comprising a glutamine residue (Q) at an N-terminal.

Abstract: Measuring the amount of lipocalin 15 in an olfactory mucosa sample or an olfactory mucus sample taken from a mammal is useful for non-subjectively and objectively diagnosing olfactory sense and is easily applied to clinical practice.

Abstract: Compounds having an affinity substance to an antibody and a bioorthogonal functional group, represented by the following Formula (I): A-L-E-B??(I) wherein A is an affinity substance to an antibody, L is a divalent group comprising a leaving group, E is a divalent group comprising an electrophilic group (i) coupled with the leaving group and (ii) having ability to react with a nucleophilic group in the antibody, B is a bioorthogonal functional group, and the leaving group has ability to be cleaved and eliminated from E by a reaction between the nucleophilic group and the electrophilic group, or a salt thereof, and the like are useful for labelling antibodies.

Abstract: Compounds having an affinity substance to an antibody, a cleavable portion, and a reactive group, represented by the following Formula (I): A-L-B-R??(I) wherein A is the affinity substance an antibody, L is a cleavable linker which is a divalent group comprising the cleavable portion, B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group, and R is the reactive group to the antibody, in which the affinity substance to an antibody is a certain peptide, or a salt thereof are useful for the modification of an antibody, particularly the regioselective modification of an antibody.

Abstract: A novel protein deamidase having an activity of directly acting on a side chain amide group of an asparagine residue in a protein to form a side chain carboxyl group and release ammonia, a microorganism that produces the same, a gene encoding the same, a method for producing the same, and use of the same are provided. A bacterium classified into the class Actinobacteria is cultured to generate protein deamidase, and the enzyme is collected from culture.

Abstract: A novel protein deamidase having an activity of directly acting on a side chain amide group of an asparagine residue in a protein to form a side chain carboxyl group and release ammonia, a microorganism that produces the same, a gene encoding the same, a method for producing the same, and use of the same are provided. A bacterium classified into the class Actinobacteria is cultured to generate protein deamidase, and the enzyme is collected from culture.

Abstract: A novel protein deamidase having an activity of directly acting on a side chain amide group of an asparagine residue in a protein to form a side chain carboxyl group and release ammonia, a microorganism that produces the same, a gene encoding the same, a method for producing the same, and use of the same are provided. A bacterium classified into the class Actinobacteria is cultured to generate protein deamidase, and the enzyme is collected from culture.

Abstract: The present invention provides a technique enabling modification of a soluble protein and in particular regioselective modification of a soluble protein. More specifically, the present invention provides a compound having an affinity substance to a soluble protein, a cleavable portion, and a reactive group represented by the following Formula (I): A-L-B-R??(I) wherein A is an affinity substance to a soluble protein; L is a cleavable linker which is a divalent group comprising a cleavable portion; B is (a) a divalent group comprising a bioorthogonal functional group or (b) a divalent group comprising no bioorthogonal functional group; and R is a reactive group to the soluble protein; or a salt thereof.

Abstract: An evaluating method includes an evaluating step of evaluating a state of mild cognitive impairment or Alzheimer's disease for a subject to be evaluated using a concentration value of at least one of ?-ABA, Ala, Arg, Asn, Cit, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Cysteine, Taurine, GABA, Hypotaurine, S-Adenosyl homocysteine, Sarcosine, Serotonin, Spermidine, hCit, 3-hKyn, aAiBA, N8-Acetylspermidine, Phosphoserine, bABA, ADMA, and Thioproline in blood of the subject.

Abstract: An evaluating method includes an evaluating step of evaluating a state of pancreatic cancer for a subject to be evaluated using (i) a concentration value of at least one metabolite of N-Me-bABA, bABA, GABA, N6-Acetyl-L-Lys, 1-Me-His, aABA, Aminoadipic acid, bAiBA, Cadaverine, Ethylglycine, Homoarginine, Hypotaurine, Kinurenine, Putrescine, Serotonin, Spermidine, Spermine, ADMA, Homocitrulline, 3-Me-His, Hydroxyproline, Phosphoethanolamine, Acylcarnitine (13:1), and EPA in blood of the subject or (ii) a value of a formula calculated using the concentration value of the metabolite and the formula including an explanatory variable to be substituted with the concentration value of the metabolite.

Abstract: An evaluating method includes an evaluating step of evaluating a state of colorectal cancer for a subject to be evaluated using (i) a concentration value of at least one metabolite of bABA, N-Me-bABA, 1-Me-His, aABA, Aminoadipic acid, bAiBA, Cadaverine, Ethylglycine, GABA, Homoarginine, Hypotaurine, Kinurenine, N6-Acetyl-L-Lys, Putrescine, Serotonin, Spermidine, Spermine, ADMA, Homocitrulline, 3-Me-His, Hydroxyproline, Phosphoethanolamine, SDMA, Acylcarnitine (13:1), and EPA in blood of the subject or (ii) a value of a formula calculated using the concentration value of the metabolite and the formula including an explanatory variable to be substituted with the concentration value of the metabolite.

Abstract: An evaluating method includes an evaluating step of evaluating future risk of developing Alzheimer's disease for a subject to be evaluated having mild cognitive impairment using a concentration value of at least one of ?-ABA, Ala, Arg, Asn, Cit, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Cysteine, Taurine, bABA, Ethylglycine, Hypotaurine, 3-Me-His, 5-HydroxyTrp, aAiBA, and N8-Acetylspermidine in blood of the subject.

Abstract: Enantiomers may be analyzed by: (1) reacting a mixture of a first compound and a second compound that are a pair of enantiomers with an axially chiral compound that is one of a pair of axially chiral isomers, to generate a derivative mixture containing a first derivative obtained by a reaction of the first compound with the axially chiral compound and a second derivative obtained by a reaction of the second compound with the axially chiral compound; (2) separating the first derivative and the second derivative in the derivative mixture; and (3) detecting the separated first derivative and second derivative by mass spectrometry.

Abstract: An external standard solution for use in the analysis of amino acid in plasma, containing, (1) at least one amino acid selected from the following components A, at a concentration of 0.0007 M to 0.49 M, and (2) (i) at least one amino acid selected from the following components B, at a concentration of 0.2 to 0.9 times of the lowest-concentration amino acid among the amino acids selected from components A, (ii) at least one amino acid selected from the following components C, at a concentration of 0.1 to 0.4 times of the lowest-concentration amino acid among amino acids selected from the components A, or (iii) at least one amino acid selected from the following components D, at a concentration of 0.05 to 0.

Abstract: An evaluating method includes an evaluating step of evaluating a state of lung cancer for a subject to be evaluated using a concentration value of at least one of Homoarginine, GABA, 3-Me-His, ADMA, Spermine, Spermidine, Cystathionine, Sarcosine, aAiBA, bAiBA, Putrescine, N-Acetyl-L-lys, Hypotaurine, bABA, and Ethylglycine in blood of the subject.